Evidence map›Paper›PMID 28640622›Full record

ReviewChemical reviews2017

Catalytic Asymmetric Synthesis of Butenolides and Butyrolactones.

Bin Mao, Martín Fañanás-Mastral, Ben L Feringa

Abstract readReview
In one paragraph

Review in Chemical reviews, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Enantioselective Synthesis of (+)-Auriculatol A.Journal of the American Chemical Society · 2025
    Article
  7. Article
  8. Article
  9. Journal of the American Chemical Society · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Versatile Copper-Catalyzed γ-C(spJournal of the American Chemical Society · 2024
    Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Bin MaoStratingh Institute for Chemistry, University of Groningen , Nijenborg 4, 9747 AG Groningen, The Netherlands.
Martín Fañanás-MastralStratingh Institute for Chemistry, University of Groningen , Nijenborg 4, 9747 AG Groningen, The Netherlands.ORCID http://orcid.org/0000-0003-4903-0502
Ben L FeringaStratingh Institute for Chemistry, University of Groningen , Nijenborg 4, 9747 AG Groningen, The Netherlands.ORCID http://orcid.org/0000-0003-0588-8435

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

γ-Butenolides, γ-butyrolactones, and derivatives, especially in enantiomerically pure form, constitute the structural core of numerous natural products which display an impressive range of biological activities which are important for the development of novel physiological and therapeutic agents. Furthermore, optically active γ-butenolides and γ-butyrolactones serve also as a prominent class of chiral building blocks for the synthesis of diverse biological active compounds and complex molecules. Taking into account the varying biological activity profiles and wide-ranging structural diversity of the optically active γ-butenolide or γ-butyrolactone structure, the development of asymmetric synthetic strategies for assembling such challenging scaffolds has attracted major attention from synthetic chemists in the past decade. This review offers an overview of the different enantioselective synthesis of γ-butenolides and γ-butyrolactones which employ catalytic amounts of metal complexes or organocatalysts, with emphasis focused on the mechanistic issues that account for the observed stereocontrol of the representative reactions, as well as practical applications and synthetic potentials.

Indexed as

4-ButyrolactoneCatalysisLactonesMolecular StructureOrganometallic CompoundsStereoisomerism4-ButyrolactonebutenolideLactonesOrganometallic Compounds

Identifiers

PMID28640622
PMCPMC5553117

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.